AI Portfolio Summary
In 2025 Q4, BAKER BROS. ADVISORS LP maintained a portfolio of 99 distinct positions. They heavily accumulated shares in Incyte Corporation, increasing their position by 0.0%. Conversely, BAKER BROS. ADVISORS LP completely exited their position in Merus N.V..
Total Positions
99
Quarter
2025 Q4
Top Holding
INCY (17.8%)
Top 10 Concentration
74.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 99
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
INCY
Incyte Corporat...
|
Healthcare | 17.78% | 18.84% |
#1
1
Prev: #2
|
9.1 | 328 | 0.0% |
P
S
|
30,743,991 | $3,036,583,991 | 2003 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ONC
BeOne Medicines...
|
Healthcare | 15.65% | 21.66% |
#2
1
Prev: #1
|
6.3 | no change | no change |
P
S
|
8,799,053 | $2,673,240,292 | 2016 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MDGL
Madrigal Pharma...
|
Healthcare | 7.30% | 7.10% |
#3
Prev: #3
|
2.9 | no change | no change |
P
S
|
2,141,701 | $1,247,198,160 | 2016 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSM
Insmed Incorpor...
|
Healthcare | 6.72% | 6.98% |
#4
Prev: #4
|
2.7 | -110,738 | -1.7% |
P
S
|
6,592,746 | $1,147,401,514 | 2012 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACAD
ACADIA Pharmace...
|
Healthcare | 6.71% | 6.61% |
#5
Prev: #5
|
2.7 | no change | no change |
P
S
|
42,896,690 | $1,145,770,590 | 2005 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CELC
Celcuity Inc.
|
Healthcare | 4.62% | 2.83% |
#6
3
Prev: #9
|
1.8 | no change | no change |
P
S
|
7,915,792 | $789,521,094 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
Revolution Medi...
|
Healthcare | 4.41% | 3.19% |
#7
1
Prev: #8
|
1.8 | no change | no change |
P
S
|
9,455,357 | $753,119,185 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYMR
Kymera Therapeu...
|
Healthcare | 3.94% | 2.72% |
#8
2
Prev: #10
|
3.7 | 2,005,813 | 30.2% |
P
S
|
8,657,242 | $673,620,000 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SMMT
Summit Therapeu...
|
Healthcare | 3.73% | 5.03% |
#9
3
Prev: #6
|
3.5 | 2,668,089 | 7.9% |
P
S
|
36,391,063 | $636,479,692 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RYTM
Rhythm Pharmace...
|
Healthcare | 3.51% | 4.09% |
#10
3
Prev: #7
|
1.4 | no change | no change |
P
S
|
5,604,483 | $599,903,860 | 2017 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KOD
Kodiak Sciences...
|
Healthcare | 3.26% | 2.05% |
#11
Prev: #11
|
3.3 | 2,608,696 | 15.1% |
P
S
|
19,919,186 | $556,940,441 | 2018 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
Praxis Precisio...
|
Healthcare | 1.94% | 0.26% |
#12
24
Prev: #36
|
3.0 | 437,000 | 63.4% |
P
S
|
1,126,488 | $332,021,073 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
Alkermes plc
|
Healthcare | 1.64% | 1.75% |
#13
1
Prev: #12
|
2.7 | 1,920,916 | 23.7% |
P
S
|
10,012,267 | $280,143,231 | 2003 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GRAL
GRAIL, Inc.
|
Healthcare | 1.05% | 0.70% |
#14
4
Prev: #18
|
2.5 | 455,208 | 27.9% |
P
S
|
2,085,333 | $178,483,651 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
Edgewise Therap...
|
Healthcare | 0.96% | 0.86% |
#15
1
Prev: #14
|
0.4 | -730,000 | -10.0% |
P
S
|
6,575,940 | $163,181,951 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARWR
Arrowhead Pharm...
|
Healthcare | 0.85% | 0.42% |
#16
9
Prev: #25
|
2.4 | 504,883 | 30.2% |
P
S
|
2,175,645 | $144,441,072 | 2013 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IONS
Ionis Pharmaceu...
|
Healthcare | 0.83% | 0.27% |
#17
18
Prev: #35
|
2.6 | 1,225,043 | 216.1% |
P
S
|
1,791,841 | $141,752,542 | 2006 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMVT
Immunovant, Inc...
|
Healthcare | 0.81% | 0.64% |
#18
2
Prev: #20
|
0.3 | no change | no change |
P
S
|
5,457,881 | $138,739,335 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMTX
Immatics N.V.
|
Healthcare | 0.74% | 0.74% |
#19
2
Prev: #17
|
0.3 | no change | no change |
P
S
|
12,094,094 | $126,987,987 | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IDYA
IDEAYA Bioscien...
|
Healthcare | 0.73% | 0.64% |
#20
1
Prev: #19
|
2.3 | 343,382 | 10.5% |
P
S
|
3,618,826 | $125,102,815 | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ROIV
Roivant Science...
|
Healthcare | 0.71% | 0.41% |
#21
5
Prev: #26
|
2.4 | 1,787,244 | 47.4% |
P
S
|
5,555,017 | $120,543,869 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
Abivax S.A.
|
Healthcare | 0.69% | 0.54% |
#22
2
Prev: #24
|
0.3 | no change | no change |
P
S
|
875,796 | $118,105,470 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KNSA
Kiniksa Pharmac...
|
Healthcare | 0.68% | 0.79% |
#23
8
Prev: #15
|
2.3 | 1,577 | 0.1% |
P
S
|
2,826,246 | $116,582,648 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REPL
Replimune Group...
|
Healthcare | 0.63% | 0.33% |
#24
6
Prev: #30
|
0.3 | no change | no change |
P
S
|
11,045,336 | $107,360,666 | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STOK
Stoke Therapeut...
|
Healthcare | 0.62% | 0.79% |
#25
9
Prev: #16
|
0.3 | -1,297,141 | -28.0% |
P
S
|
3,336,697 | $105,906,763 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
Merus N.V.
|
Healthcare | 0.00% | 0.39% |
Sold All 😨
(Was: #28) |
0.3 | -574,377 | -100.0% |
CLOSED
|
— | $— | 2016 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTLA
Intellia Therap...
|
Healthcare | 0.00% | 0.34% |
Sold All 😨
(Was: #29) |
0.3 | -2,746,674 | -100.0% |
CLOSED
|
— | $— | 2016 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RNA
Avidity Bioscie...
|
Healthcare | 0.00% | 0.20% |
Sold All 😨
(Was: #43) |
0.3 | -625,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
Vaxcyte, Inc.
|
Healthcare | 0.00% | 0.17% |
Sold All 😨
(Was: #44) |
0.3 | -640,885 | -100.0% |
CLOSED
|
— | $— | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
Cidara Therapeu...
|
Healthcare | 0.00% | 0.16% |
Sold All 😨
(Was: #46) |
0.3 | -227,272 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKRO
Akero Therapeut...
|
Healthcare | 0.00% | 0.11% |
Sold All 😨
(Was: #52) |
0.3 | -324,630 | -100.0% |
CLOSED
|
— | $— | 2020 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
Arcellx, Inc.
|
Healthcare | 0.00% | 0.10% |
Sold All 😨
(Was: #56) |
0.3 | -166,825 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VKTX
Viking Therapeu...
|
Healthcare | 0.00% | 0.07% |
Sold All 😨
(Was: #64) |
0.3 | -366,083 | -100.0% |
CLOSED
|
— | $— | 2018 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
Agios Pharmaceu...
|
Healthcare | 0.00% | 0.06% |
Sold All 😨
(Was: #66) |
0.3 | -189,866 | -100.0% |
CLOSED
|
— | $— | 2013 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HRTX
Heron Therapeut...
|
Healthcare | 0.00% | 0.04% |
Sold All 😨
(Was: #72) |
0.3 | -4,251,951 | -100.0% |
CLOSED
|
— | $— | 2014 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX Biosciences...
|
Healthcare | 0.00% | 0.04% |
Sold All 😨
(Was: #74) |
0.3 | -277,777 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
Generation Bio ...
|
—
|
Unknown | 0.00% | 0.01% |
Sold All 😨
(Was: #84) |
0.3 | -194,493 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
VYNE
VYNE Therapeuti...
|
Healthcare | 0.00% | 0.00% |
Sold All 😨
(Was: #87) |
0.3 | -851,353 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 99 holdings